Genix Cure is focused on developing advanced AAV (adeno-associated virus) vectors through its proprietary CARE™ platform, which aims to create recombinant AAVs that are more targeted and less toxic to specific cell types. This innovative approach is designed to overcome the clinical limitations of AAV gene therapies, particularly in treating genetic mutations associated with neurodegenerative diseases. The company is dedicated to developing first-in-class therapies for rare diseases, leveraging its expertise in AAV vector engineering to provide solutions for conditions such as ALS (amyotrophic lateral sclerosis) and Lafora disease.

In addition to its therapeutic development efforts, Genix Cure offers non-GMP CDMO (Contract Development and Manufacturing Organization) services, supplying AAV materials for preclinical studies to both domestic and international research institutions and private companies. The company has established standard operating procedures (SOPs) for various AAV serotypes, ensuring a reliable supply of AAV substances for non-clinical trials. Furthermore, Genix Cure is recognized for its AI-based gene therapy development platform, which enhances its capabilities in AAV vector engineering, thereby positioning the company as a leader in the gene therapy sector.

Pakistan

At Genix Cure, we're on a mission to redefine well-being through the power of nature. We craft innovative, natural remedies that promote health and vitality, utilizing the genesis of nature's ingredients. Our commitment to authenticity and purity ensures that our products can be consumed daily, fostering wellness without compromise. Join us on our journey to a healthier, more rejuvenated life, where we believe that the path to well-being begins with nature's own genesis.

Genix Cure

Company Details